Prelude Therapeutics Incorporated
Balance Sheet
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $26.3M | $21.8M | $35.3M | $47.5M | $25.8M | $40.3M | $12.5M | $11.1M |
| Accounts Receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $154.9M | $84.6M | $105.7M | $58.3M | $76.9M | $102.4M | $135.9M | $156.4M |
| Property, Plant & Equipment | $4.4M | $4.7M | $5.1M | $5.5M | $6.0M | $6.4M | $6.8M | $7.2M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $189.4M | $119.6M | $141.3M | $94.8M | $114.9M | $141.3M | $175.5M | $197.2M |
| Liabilities | ||||||||
| Accounts Payable | $2.0M | $2.1M | $4.0M | $2.5M | $5.0M | $5.8M | $7.7M | $5.9M |
| Total Current Liabilities | $38.0M | $41.7M | $53.0M | $18.2M | $20.9M | $19.8M | $25.6M | $22.2M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $55.6M | $59.5M | $72.7M | $36.2M | $39.1M | $38.1M | $44.1M | $40.8M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-707.4M | $-693.4M | $-683.1M | $-666.6M | $-646.9M | $-615.6M | $-583.6M | $-554.8M |
| Total Stockholders' Equity | $133.7M | $60.2M | $68.6M | $58.5M | $75.8M | $103.2M | $131.5M | $156.4M |